DESMOPRESSIN ACETATE

Clinical safety rating: safe

Animal studies have demonstrated safety

How it works

Desmopressin acetate is a synthetic analog of antidiuretic hormone (ADH) that binds to V2 receptors in the renal collecting ducts, increasing water reabsorption and reducing urine output. It also stimulates release of von Willebrand factor and factor VIII from endothelial cells via V2 receptor activation.

What the body does with it

Metabolism	Desmopressin undergoes minimal hepatic metabolism. It is primarily metabolized by reduction of the disulfide bond, with subsequent proteolytic cleavage. CYP450 enzymes are not involved.
Excretion	Renal (60-70% unchanged), minimal biliary/fecal (<10%)
Half-life	Terminal half-life 2-4 hours; prolonged in renal impairment (up to 9 hours)
Protein binding	50-60%, primarily to albumin
Volume of Distribution	0.3-0.5 L/kg, indicating distribution into total body water
Bioavailability	Intranasal: 3-5%; Oral: 0.1-0.5%
Onset of Action	Intravenous: 15-30 minutes; Intranasal: 30-60 minutes; Oral: 60-180 minutes
Duration of Action	Intravenous: 6-12 hours; Intranasal: 8-12 hours; Oral: 6-12 hours; duration dose-dependent

Classification & Brands

Dosing & administration

IV/SC: 0.3-0.4 mcg/kg IV/SC once; may repeat once after 24 hours. Intranasal: 100-400 mcg (0.1-0.4 mL) once; may repeat once after 24 hours. Oral: 300-600 mcg three times daily.

Dosage form	INJECTABLE
Renal impairment	eGFR <30 mL/min/1.73m2: contraindicated. eGFR 30-50: reduce dose by 50% and monitor sodium. eGFR >50: no adjustment.
Liver impairment	No specific guidelines; caution in severe hepatic impairment due to potential fluid/electrolyte disturbances.
Pediatric use	Hemophilia A/vWD: IV/SC 0.3 mcg/kg diluted in 50 mL NS over 15-30 min. Nocturnal enuresis: oral 200-600 mcg at bedtime; intranasal 100-400 mcg at bedtime. Diabetes insipidus: oral 100-200 mcg three times daily; intranasal 50-100 mcg twice daily.
Geriatric use	Start at lower end of dosing range; monitor serum sodium and fluid balance due to increased risk of hyponatremia. Avoid in patients with known hyponatremia or renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Other drugs that may increase the risk of water intoxication and hyponatremia Can cause hyponatremia and water intoxication monitor sodium levels.

Breastfeeding	Limited data; desmopressin is excreted in breast milk in small amounts (M/P ratio unknown, estimated <1% of maternal dose). Oral desmopressin is considered compatible with breastfeeding due to minimal oral bioavailability in infants. Caution with high doses or intranasal route.
Teratogenic Risk	FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; no increased risk of congenital anomalies reported. Use during pregnancy only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Not applicable for this drug. No FDA black box warning.

Side Effect Profile

Common Effects	enuresis
Serious Effects

Absolute Contraindications

["Hypersensitivity to desmopressin or any component of the formulation","Moderate to severe renal impairment (CrCl <50 mL/min)","Hyponatremia or history of hyponatremia","Known platelet type von Willebrand disease","Uncontrolled hypertension or coronary artery disease (for hemostatic use)"]

Clinical Precautions

Precautions

["Risk of hyponatremia and water intoxication, especially in patients with increased fluid intake or conditions predisposing to hyponatremia","Monitor serum sodium levels in high-risk patients","Use with caution in patients with cystic fibrosis, renal impairment, or electrolyte imbalances","May cause thrombotic events in predisposed patients when used for hemostatic indications"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…